The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells

12Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

It has been reported that phytoestrogen epigallocatechin gallate (EGCG) suppresses cancer cell proliferation and may have antitumor properties. In this study, we analyzed the effects of EGCG on estrogen receptor α (ERα) and progesterone receptor in hormone-dependent T-47D breast cancer cells. Western blot analysis revealed EGCG induced a concentration-dependent decrease in ERα protein levels, with a 56% reduction occurring with 60 μM EGCG when compared to controls. Downregulation of ERα protein levels was observed after 24-hour cotreatment of T-47D cells with 60 μM EGCG and 10 nM 17β-estradiol (E2). The proliferative effect of E2 on cell viability was reversed when treated in combination with EGCG. In contrast, the combination of EGCG with the pure ER antagonist, ICI 182, 780, showed no further reduction in cell number as only 5% of the cells were viable after 6 days of treatment. These studies may provide further understanding of the interactions among flavonoids and steroid receptors in breast cancer cells.

Author supplied keywords

Cite

CITATION STYLE

APA

Hallman, K., Aleck, K., Quigley, M., Dwyer, B., Lloyd, V., Szmyd, M., & Dinda, S. (2017). The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells. Breast Cancer: Targets and Therapy, 9, 365–373. https://doi.org/10.2147/BCTT.S131334

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free